Context In patients treated for prostate cancer, a rising serum prostate-specific antigen (PSA)
level is a first sign of relapse, but imaging is needed to determine the localization of the …

Background: The use of radiolabeled prostate-specific membrane antigen positron emission
tomography/computed tomography (PSMA PET/CT) for biochemical recurrent prostate …

Prostate-specific membrane antigen (PSMA)–targeted PET imaging recently emerged as a
new method for the staging and restaging of prostate cancer. Most published studies …

Purpose The primary aim of this retrospective, single-centre analysis was to assess the
performance of 68 Ga-PSMA-11 PET/CT in prostate cancer (PCa) patients in early PSA …

Abstract Introduction [18F] PSMA-1007 has potential advantages over [68 Ga] Ga-PSMA-11,
although limited prospective data evaluating diagnostic performance exist. The aims of this …

Purpose The introduction of ligands targeting prostate-specific membrane antigen (PSMA),
especially 68 Ga-PSMA-11, has changed the management of patients with prostate cancer …

Candidates for prostate-specific membrane antigen (PSMA)-targeted radioligand therapy
(RLT) of metastatic castration-resistant prostate cancer (mCRPC) frequently have …

Background National guidelines endorse fluorine 18 (18F) fluciclovine PET/CT for the
detection of prostate cancer (PCa) in men with biochemically recurrent PCa. The …

Background: The rising incidence rate of prostate cancer (PCa) has promoted the
development of new diagnostic and therapeutic radiopharmaceuticals during the last …

Prostate cancer (PCa) faces great challenges in early diagnosis, which often leads not only
to unnecessary, invasive procedures, but to over-diagnosis and treatment as well, thus …